MGMT and melanoma: Glioblastomas [87] and stage IV melanomas [88] with MGMT methylation respond better to treatment with alkylating agents (temozolomide and dacarbazine), and MGMT methylation is an independent variable associated with disease-free [88] and overall survival [87].